Leona Plum-Mörschel
11Publications
5H-index
207Citations
Publications 11
Newest
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 19.31
Inge B Halberg1
Estimated H-index: 1
(Novo Nordisk),
Karsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
+ 3 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Summary Background Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. Methods This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequatel...
3 Citations Source Cite
Published on May 1, 2018in Hormone and Metabolic Research 2.56
Thomas Forst37
Estimated H-index: 37
(University of Mainz),
Mohammed Khaled Alghdban1
Estimated H-index: 1
(University of Mainz)
+ 5 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation. Twenty-six patients (19 males, age 63.5±7.0 years; duration of diabetes 8.8±4.7 years; HbA1c 63.9±15.8 mmol/mol; mean±SD) were enrolled in the study. During a first treatment period (TP1) all patients received 10 mg dapagliflozin for one month, followed by the ad...
1 Citations Source Cite
Published on May 1, 2018in Diabetes, Obesity and Metabolism 5.98
Eric Zijlstra9
Estimated H-index: 9
,
Hans-Veit Coester4
Estimated H-index: 4
+ 6 AuthorsThomas Sparre14
Estimated H-index: 14
(Novo Nordisk)
1 Citations Source Cite
Published on Apr 1, 2017in Diabetes, Obesity and Metabolism 5.98
Thomas Forst37
Estimated H-index: 37
(University of Mainz),
Alexander Falk1
Estimated H-index: 1
+ 6 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Aims The aim of the study was to investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of alpha- and beta cell function in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy. Methods Forty-four patients with T2DM received 25 mg empagliflozin for a duration of one month in an open-label fashion (treatment period (TP 1). Thereafter, patients were randomised to a double-blind add-on therapy wi...
6 Citations Source Cite
Published on Oct 1, 2016in Diabetes, Obesity and Metabolism 5.98
Tim Heise40
Estimated H-index: 40
,
Eric Zijlstra9
Estimated H-index: 9
+ 3 AuthorsThomas Forst37
Estimated H-index: 37
The hyperinsulinaemic-euglycaemic glucose clamp has always been regarded as the "gold standard" for the assessment of pharmacodynamic (PD) properties of insulin preparations; however, there has been controversy over a variety of methodogical details, such as study population, dosing time and the initial stabilization of blood glucose (BG) concentrations at the clamp target level, among clamp groups. As the impact of these details on PD results is unclear, the present review provides an overview ...
16 Citations Source Cite
Published on Oct 26, 2016in Current Diabetes Reviews
Thomas Forst37
Estimated H-index: 37
,
Tim Heise40
Estimated H-index: 40
,
Leona Plum-Mörschel5
Estimated H-index: 5
Introduction: In recent years, numerous pharmacological approaches for the treatment of type 2 diabetes mellitus (T2DM) have become available. While all of them have proven blood glucose-lowering effects, identifying the most beneficial drug or drug combination for the treatment of an individual patient has become an increasing challenge. Several guidelines attempt to provide decision criteria based on clinical characteristics and comorbidities in patients with T2DM, however, these guidelines st...
Source Cite
Published on Feb 1, 2015in Diabetes, Obesity and Metabolism 5.98
Sue Sha9
Estimated H-index: 9
(Janssen Pharmaceutica),
David Polidori22
Estimated H-index: 22
(Janssen Pharmaceutica)
+ 6 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Aims To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co-transporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin on urinary glucose excretion (UGE), renal threshold for glucose excretion (RTG) and postprandial plasma glucose (PPG) excursion in healthy participants in a randomized, double-blind, two-period crossover study. Methods In each treatment period, participants (n = 54) received canagliflozin 300 mg or dapagliflozin 10 mg for 4 days (20 m...
39 Citations Source Cite
Published on Nov 1, 2014in Diabetes, Obesity and Metabolism 5.98
Sue Sha9
Estimated H-index: 9
(Janssen Pharmaceutica),
David Polidori22
Estimated H-index: 22
(Janssen Pharmaceutica)
+ 6 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Aim To evaluate the effects of canagliflozin on plasma volume, urinary glucose excretion (UGE), fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and additional measures of fluid/electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Methods Patients (N = 36) were randomized (1 : 1) to receive canagliflozin 300 mg or placebo for 12 weeks. Pharmacodynamic parameters were asse...
79 Citations Source Cite
12